Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives. Novartis works closely with healthcare professionals around the world to support ...
Novartis applauds Ontario’s bold leadership in launching the FAST program, which accelerates access to breakthrough therapies like Scemblix ® for patients living with cancer. Scemblix ® (asciminib) ...
חפשו אחר אפשרויות תעסוקה בחברת נוברטיס וסנדוז. לתפקידים נוספים ב Novartis Gene Therapies (formerly AveXis) בקרו בGTx Career Search הודעה למתמודדים על משרות בארה"ב.
Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.
Novartis heeft wereldwijd zowat 119.000 medewerkers waarvan er 2000 in België werken. Het aantrekken van getalenteerde mensen, hen ontwikkelen en behouden is van cruciaal belang voor ons. Daarmee ...
Below is a list of the treatments we currently offer via our Innovative Medicines Division. Visit Sandoz and Advanced Accelerator Applications to learn about our generics and radiopharmaceutical ...
استكشف الفرص مع نوفارتس أدناه.
ノバルティス ファーマ株式会社（本社：東京都港区、代表取締役社長：ジョンポール・プリシーノ）（以下「ノバルティス ファーマ」）は、日本の前立腺がんの治療経験に基づく視点を ...
Geplante Investitionen in die Schweizer Produktionsstandorte von über USD 100 Mio. – USD 80 Mio. am Standort Schweizerhalle in die Herstellung von siRNA und USD 26 Mio. in die Produktion steriler ...
Asciminib (Scemblix®) nun auch zur Behandlung erwachsener Patient*innen mit neu diagnostizierter CML zugelassen1Zulassung basiert auf Ergebnissen der Phase-III ...
Basel, November 20, 2025 – Novartis today rolled forward its mid-term guidance to 2025-2030 with a sales CAGR of +5-6% cc. The updated outlook will be featured at its Meet Novartis Management event in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback